FDA Grants Accelerated Approval for Alzheimer’s drug Aduhelm
Posted on10 Jun 2021
Tagsaducanumab, Aduhelm, Biogen, Eisai, global pharma licensing deal, monoclonal antibody, Neurimmune, pharma deal
Comments0
USFDA approved Aduhelm (aducanumab) for the treatment of Alzheimer disease. Alzheimer’s drug Aduhelm is research molecule of Neurimmune. Neurimmune licensed its antibody... Read More
Insight of BioInvent’s licensing deal of anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals
BioInvent licenses anti-FcγRllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region. BioInvent have entered into an exclusive licensing agreement for the... Read More
Gilead’s Voluntary Licensing Agreements for Remdesivir with 5 generic companies
Posted on13 May 2020
Tagsdrug licensing, gilead, global pharma licensing deal, licensing deal in pharma, mylan licensing deal, nonexclusive, Remdesivir
Comments0
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand supply of remdesivir.... Read More
RIBOMIC – AJU Pharma licensing deal for RBM-007 in age-related macular degeneration
Posted on20 Mar 2020
Comments0
RBOMIC has finalized the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company. This deal is for RBM-007 licensing agreement for... Read More
Insight on Hikma and Glenmark’s Exclusive Licensing Agreement for Commercialising Ryaltris Nasal Spray in the US
Posted on28 Feb 2020
Tagsdrug licensing, Glemark outlicensing, Glenmark, global pharma licensing deal, Hikma, inlicensing in pharma, Ryaltris
Comments0
Hikma Pharmaceuticals PLC and Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals, a global innovative pharmaceutical company signed of an exclusive... Read More
Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
South Korean company Alteogen Inc. signed a nonexclusive global license agreement with a top 10 global pharmaceutical company for its recombinant human... Read More
Clovis in-licensing deal for cancer program from 3B Pharmaceuticals
Clovis Oncology inks an agreement with privately held 3B Pharmaceuticals GmbH for global rights (ex. Europe, Russia, Turkey and Israel) to a... Read More
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Posted on12 Sep 2019
Comments0
Alexion Pharmaceuticals announced a license agreement with BridgeBio Pharma’s subsidiary Eidos Therapeutics. Per the terms of the deal, Alexion will obtain an... Read More
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
Posted on07 Feb 2019
TagsGlemark outlicensing, global pharma licensing deal, licensing deal in pharma, outlicensing in pharma
Comments0
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, announced that its Swiss subsidiary, Glenmark Specialty S.A, has entered into an exclusive... Read More
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Daiichi Sankyo and AnHeart Therapeutics announced they have entered into a worldwide exclusive license agreement for DS-6051, Daiichi Sankyo’s selective ROS1/NTRK inhibitor,... Read More